We’re building a TCAP platform to address many neuropsychiatric disorders and other neurodegenerative diseases that are impacted by the stress response system of the brain.
We’ve spent the last several years building a robust preclinical pharmacology package for PT00114, and have completed enabling studies to enter the clinic in Q3 2022.
We will be conducting our first clinical study in collaboration with Harvard/MGH and Dr. Maurizio Fava, a world-renowned psychiatrist and major voice in the effort to find new, effective treatments for patients with depression, anxiety, PTSD, and other stress-related diseases.
© 2022 Protagenic Therapeutics, Inc.
Built by Techtegic
